The field of cancer immunology has witnessed dramatic progress with the advent of immunotherapies targeting the tumor immune microenvironment (TIME).
Researchers at St. Jude Children's Research Hospital have uncovered a new pathway for mitochondrial cell death that involves the protein BCL-2 ovarian killer, otherwise known as BOK. The discovery, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback